Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Argos Therapeutics Inc stock logo
ARGSQ
Argos Therapeutics
$0.05
$0.05
$0.02
$0.25
$572K2.4713,394 shsN/A
Biostar Pharmaceuticals, Inc. stock logo
BSPM
Biostar Pharmaceuticals
$0.00
$0.00
$0.00
N/A-2.3N/AN/A
HSTC
HST Global
$0.28
$0.61
$0.23
$1.10
$15.89M-1.24213 shsN/A
SKVI
Skinvisible
$0.20
$0.21
$0.16
$0.85
$1.08M1.7692 shs70 shs
TRPXD
Therapix Biosciences
$0.00
$2.75
$22.40
$299KN/A1,852 shs900 shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Argos Therapeutics Inc stock logo
ARGSQ
Argos Therapeutics
0.00%0.00%0.00%0.00%0.00%
Biostar Pharmaceuticals, Inc. stock logo
BSPM
Biostar Pharmaceuticals
0.00%0.00%0.00%0.00%+∞
HSTC
HST Global
0.00%-8.64%-46.29%-46.08%-73.81%
SKVI
Skinvisible
0.00%-9.09%+13.44%-33.33%-71.01%
TRPXD
Therapix Biosciences
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Argos Therapeutics Inc stock logo
ARGSQ
Argos Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Biostar Pharmaceuticals, Inc. stock logo
BSPM
Biostar Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
HSTC
HST Global
N/AN/AN/AN/AN/AN/AN/AN/A
SKVI
Skinvisible
N/AN/AN/AN/AN/AN/AN/AN/A
TRPXD
Therapix Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Argos Therapeutics Inc stock logo
ARGSQ
Argos Therapeutics
0.00
N/AN/AN/A
Biostar Pharmaceuticals, Inc. stock logo
BSPM
Biostar Pharmaceuticals
0.00
N/AN/AN/A
HSTC
HST Global
0.00
N/AN/AN/A
SKVI
Skinvisible
0.00
N/AN/AN/A
TRPXD
Therapix Biosciences
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Argos Therapeutics Inc stock logo
ARGSQ
Argos Therapeutics
$1.90M0.30N/AN/A($1.63) per share-0.03
Biostar Pharmaceuticals, Inc. stock logo
BSPM
Biostar Pharmaceuticals
N/AN/AN/AN/AN/AN/A
HSTC
HST Global
N/AN/AN/AN/AN/AN/A
SKVI
Skinvisible
$20K54.00N/AN/A($1.86) per share-0.11
TRPXD
Therapix Biosciences
N/AN/AN/AN/A$0.28 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Argos Therapeutics Inc stock logo
ARGSQ
Argos Therapeutics
-$40.57MN/A0.00N/AN/AN/AN/AN/A
Biostar Pharmaceuticals, Inc. stock logo
BSPM
Biostar Pharmaceuticals
N/AN/A0.00N/AN/AN/AN/AN/AN/A
HSTC
HST Global
-$150K-$0.02N/AN/AN/AN/AN/AN/A
SKVI
Skinvisible
-$570K-$0.10N/AN/A-2,780.00%N/A-359.02%N/A
TRPXD
Therapix Biosciences
-$4.79MN/A0.00N/AN/AN/AN/AN/AN/A

Latest ARGSQ, SKVI, TRPXD, BSPM, and HSTC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
SKVI
Skinvisible
N/A-$0.05N/A-$0.05N/A$0.01 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Argos Therapeutics Inc stock logo
ARGSQ
Argos Therapeutics
N/AN/AN/AN/AN/A
Biostar Pharmaceuticals, Inc. stock logo
BSPM
Biostar Pharmaceuticals
N/AN/AN/AN/AN/A
HSTC
HST Global
N/AN/AN/AN/AN/A
SKVI
Skinvisible
N/AN/AN/AN/AN/A
TRPXD
Therapix Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Argos Therapeutics Inc stock logo
ARGSQ
Argos Therapeutics
N/AN/AN/A
Biostar Pharmaceuticals, Inc. stock logo
BSPM
Biostar Pharmaceuticals
N/AN/AN/A
HSTC
HST Global
N/AN/AN/A
SKVI
Skinvisible
N/A
0.01
0.01
TRPXD
Therapix Biosciences
N/A
0.49
N/A

Institutional Ownership

CompanyInstitutional Ownership
Argos Therapeutics Inc stock logo
ARGSQ
Argos Therapeutics
N/A
Biostar Pharmaceuticals, Inc. stock logo
BSPM
Biostar Pharmaceuticals
N/A
HSTC
HST Global
N/A
SKVI
Skinvisible
N/A
TRPXD
Therapix Biosciences
14.32%
CompanyEmployeesShares OutstandingFree FloatOptionable
Argos Therapeutics Inc stock logo
ARGSQ
Argos Therapeutics
12210.59 millionN/ANot Optionable
Biostar Pharmaceuticals, Inc. stock logo
BSPM
Biostar Pharmaceuticals
200N/AN/ANot Optionable
HSTC
HST Global
157.77 million19.75 millionNot Optionable
SKVI
Skinvisible
25.40 million2.54 millionNot Optionable
TRPXD
Therapix Biosciences
850,000N/ANot Optionable

Recent News About These Companies

TRON (CRYPTO: TRX)
Paddle Healthy: TRX Workout
Dead: RAM 1500 TRX
2024 Ram 1500 TRX Final Edition Brings the End
T. Rowe Price Retirement I 2040 I
2022 Ram 1500 TRX

Media Sentiment Over Time

Argos Therapeutics stock logo

Argos Therapeutics OTCMKTS:ARGSQ

$0.05 0.00 (0.00%)
As of 10/10/2019

Argos Therapeutics, Inc., an immuno-oncology company, focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America. The company develops immunotherapies based on its proprietary technology platform, Arcelis. Its product candidates include rocapuldencel-T, which is in Phase III clinical trial for the treatment of metastatic renal cell carcinoma. The company also develops AGS-004, which is in Phase II clinical trials for the treatment of human immunodeficiency virus. The company was formerly known as Merix Bioscience, Inc. and changed its name to Argos Therapeutics, Inc. in October 2004. Argos Therapeutics, Inc. was founded in 1997 and is based in Durham, North Carolina. On November 30, 2018, Argos Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the District of Delaware.

Biostar Pharmaceuticals stock logo

Biostar Pharmaceuticals OTCMKTS:BSPM

Biostar Pharmaceuticals, Inc. develops, manufactures, and markets over-the-counter (OTC) and prescription pharmaceutical products for various diseases and conditions in the People's Republic of China. The company principally offers Xin Ao Xing Oleanolic Acid capsule, an OTC medicine for chronic hepatitis B. It also provides 12 other OTC products and 17 prescription-based pharmaceuticals. The company's OTC products also comprise Ganwang compound paracetamol and amantadine hydrochloride capsule for the relief of common cold, runny nose, sore throat, headache, and fever; Tianqi Dysmenorrhea capsule, a traditional Chinese medicine used for pain and other symptoms associated with menstruation; Deafness Tongqiao pills for hepatobiliary Huosheng, head swelling, deafness and tinnitus, ear pus, dry stool, and urine-yellow; Wenweishu capsules for the treatment of chronic gastritis and pain of epigastric cold; Zhitongtougu ointment for treating joint pain, swelling, tenderness, or dysfunction; and Chuzhang Zehaifu tablets for cataract. Its prescription pharmaceutical products include Danshen granules; Taohuasan pediatric medicines; Jingang tablets; Danxiang Rhinitis tablets; Yanlixiao capsules; Piracetam tablets; Huangyangning tablets; Hyperthyroidism capsules; Fosfomycin Calcium capsules; Qianlietong capsules; Yituo Erythromycin particles; Danshen tablets; Muxiang Shunqi pills; Sifangwei capsules; and Aspirin Enteric-coated tablets. The company also operates a Website that serves as Internet-based China Hepatitis Internet hospital, which offers HBV patients with information on HBV and treatment options, as well as methods to purchase HBV medicines. Biostar Pharmaceuticals, Inc. sells its products through distributors and a network of sales people in approximately 28 provinces. The company was incorporated in 2007 and is headquartered in Xianyang, the People's Republic of China.

HST Global OTCMKTS:HSTC

$0.28 0.00 (0.00%)
As of 07/11/2025

HST Global, Inc., operates as an integrated health and wellness biotechnology company in the United States. The company develops and/or acquires a network of wellness centers for the homeopathic and alternative treatment of late stage cancer and other life threatening diseases. It also focuses on the homeopathic and alternative product candidates that are undergoing or have already completed clinical testing for the treatment of late stage cancer and or/ life threatening diseases. HST Global, Inc. is headquartered in Hampton, Virginia.

Skinvisible OTCMKTS:SKVI

$0.20 0.00 (0.00%)
As of 07/11/2025

Skinvisible, Inc., together with its subsidiaries, focuses on the development, manufacture, and sale of topical, transdermal, and mucosal polymer-based delivery system technologies and formulations for use in pharmaceutical, over-the-counter, personal skincare, and cosmetic arenas. Its non-dermatological formulations offer solutions for women's health, pain management, and other markets. The company's flagship product is Invisicare, a patented polymer delivery system technology that enhances the delivery of active ingredients for topically applied skin care products. It also develops and licenses prescription and over-the-counter products to pharmaceutical and consumer goods companies; assists pharmaceutical clients in the early development of the formulations; and provides solutions to pharmaceutical companies by reformulating their products coming off patent with a new Invisicare patent, and new product benefits and line extensions. The company was formerly known as Microbial Solutions, Inc. and changed its name to Skinvisible, Inc. in February 1999. Skinvisible, Inc. was incorporated in 1998 and is based in Las Vegas, Nevada.

Therapix Biosciences OTCMKTS:TRPXD

Therapix Biosciences Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include THX-110, which has completed Phase II a clinical trial for the treatment of Tourette syndrome and Obstructive Sleep Apnea; THX-160, which has completed two preliminary preclinical studies for the treatment of acute and chronic pain; and THX-210 for the treatment of autism spectrum disorder and epilepsy. The company was formerly known as NasVax Ltd. and changed its name to Therapix Biosciences Ltd. in November 2013. Therapix Biosciences Ltd. was founded in 2004 and is headquartered in Givatayim, Israel.